Emerging Company Profile
Scribe: engineering CRISPR’s next generation
Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties
Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties.
Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.